^
    4d
    Chidamide and Anlotinib act synergistically in Jurkat cells by inhibiting the Hippo signaling pathway. (PubMed, Biochem Biophys Rep)
    To overcome these limitations, we systematically evaluated the synergistic Combination effects of three drug candidates, OTX-015 (BET inhibitor), Metformin (metabolic regulator), and Anlotinib (multitargeted tyrosine kinase inhibitor), with Chidamide. Chidamide and Anlotinib synergistically inhibit Hippo signaling pathway, which reveals a novel "dual epigenetic kinase targeting" strategy for the treatment of T-ALL. Future studies should validate these findings in vivo and investigate the impact of the metabolic microenvironment on therapeutic efficacy.
    Journal
    |
    CTGF (Connective tissue growth factor)
    |
    Focus V (anlotinib) • Epidaza (chidamide) • birabresib (OTX015) • metformin
    4d
    PD-1 Antibody-based Therapy With Concurrent RT for Early-stage NKTCL (clinicaltrials.gov)
    P2, N=47, Not yet recruiting, Ruijin Hospital
    New P2 trial
    |
    Epidaza (chidamide) • golidocitinib (DZD4205)
    7d
    A Prospective, Single-Arm, Multicenter Clinical Study of Chidamide, Decitabine, PD-1 Monoclonal Antibody Combined with Pegaspargase (Epi-Immuno-Pe) in Elderly/Chemotherapy-Intolerant Patients with Relapsed or Refractory NK/T-Cell Lymphoma (ChiCTR2600117389)
    P=N/A, N=20, Not yet recruiting, The First Affiliated Hospital, Zhejiang University School of Medicine; The First Affiliated Hospital, Zhejiang University School of Medicine
    New trial
    |
    decitabine • Epidaza (chidamide) • Oncaspar liquid (pegaspargase)
    7d
    A prospective, multicenter, cocohort controlled clinical trial on the efficacy and safety of chidamide in maintenance treatment for newly diagnosed high-risk diffuse large B-cell lymphoma (ChiCTR2500112540)
    P=N/A, N=204, Not yet recruiting, The First Affiliated Hospital, Zhejiang University School of Medicine; The First Affiliated Hospital, Zhejiang University School of Medicine
    New trial
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2) • CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    |
    Epidaza (chidamide)
    7d
    TAS-102 plus Fruquintinib or TAS-102 plus Fruquintinib in combination with Chidamide and Serplulimab as third-line and beyond treatment for metastatic colorectal cancer：A multicenter, randomized, two-arm clinical trial (ChiCTR2500115578)
    P4, N=64, Not yet recruiting, The First Affiliated Hospital of Soochow University; The First Affiliated Hospital of Soochow University
    New P4 trial
    |
    Fruzaqla (fruquintinib) • Epidaza (chidamide) • Lonsurf (trifluridine/tipiracil) • Hetronifly (serplulimab)
    7d
    Clinical Study of Chidamide Combined with Azacitidine for Maintenance Therapy in Adult Acute T Lymphoblastic Leukemia/ T Lymphoblastic Lymphoma After Allogeneic Hematopoietic Stem Cell Transplantation (ChiCTR2500114134)
    P2, N=17, Not yet recruiting, The First Affiliated Hospital of Soochow University; The First Affiliated Hospital of Soochow University
    New P2 trial
    |
    azacitidine • Epidaza (chidamide)
    9d
    A Prospective, Single-Arm, Single-Center Phase II Study Evaluating the Efficacy and Safety of Chidamide Combined With PD-L1 Inhibitor, Carboplatin, and Etoposide as First-Line Treatment in Patients With Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) (clinicaltrials.gov)
    P2, N=36, Recruiting, China Medical University, China
    New P2 trial
    |
    carboplatin • etoposide IV • Epidaza (chidamide)
    11d
    QL1706 Plus Chidamide, AG as First-line Treatment for Metastatic Pancreatic Cancer (clinicaltrials.gov)
    P2, N=33, Recruiting, Tianjin Medical University Cancer Institute and Hospital | Not yet recruiting --> Recruiting
    Enrollment open
    |
    gemcitabine • albumin-bound paclitaxel • Epidaza (chidamide) • Qibeian (iparomlimab/tuvonralimab) • iparomlimab (QL1604)
    11d
    Dual epigenetic and nuclear export inhibition by chidamide and selinexor in high grade B-cell lymphomas via survivin and PI3K/AKT inhibition. (PubMed, Clin Epigenetics)
    Our preclinical data highlighted the potential synergistic efficacy of chidamide and selinexor in targeting HGBL-DHL, providing a rationale for further clinical investigation of this therapeutic combination for the treatment of this refractory disease.
    Journal
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6) • BCL2L1 (BCL2-like 1) • BIRC5 (Baculoviral IAP repeat containing 5) • CCNA2 (Cyclin A2) • ANXA5 (Annexin A5) • HDAC3 (Histone Deacetylase 3)
    |
    Xpovio (selinexor) • Epidaza (chidamide)
    11d
    ENO1 inhibition synergizes with chidamide to induce ferroptosis in PTCL-NOS through metabolic remodeling. (PubMed, Blood Sci)
    Chidamide combined with ENO1 knockdown enhanced the effect of the inhibitor on promoting apoptosis and cell cycle arrest in PTCL-NOS tumor cells. Taken together, the findings suggest that knockdown of ENO1 activates autophagy and promotes ferroptosis, thereby inhibiting PTCL-NOS cell proliferation.
    Journal
    |
    ENO1 (Enolase 1)
    |
    Epidaza (chidamide)
    17d
    S2023-056-01: Venetoclax Plus CACAG Regimen for Newly Diagnosed Acute Myeloid Leukemia (clinicaltrials.gov)
    P2, N=200, Completed, Chinese PLA General Hospital | Recruiting --> Completed
    Trial completion
    |
    Venclexta (venetoclax) • cytarabine • azacitidine • Epidaza (chidamide) • aclarubicin
    23d
    EZH2 Inhibitor Zeprumetostat in Combination Therapy for Patients With Relapsed or Refractory Mature T-cell and NK-cell Lymphomas (clinicaltrials.gov)
    P1/2, N=60, Not yet recruiting, Sun Yat-sen University
    New P1/2 trial
    |
    Epidaza (chidamide) • zeprumetostat (SHR-2554) • golidocitinib (DZD4205)